Significant company consolidation in the pharmaceutical industry is resulting in considerable surplus equipment, driving growth for the used equipment market.
The dramatic growth of high-cost biologics and specialty drugs is fueling the demand for temperature sensitive packaging.
The FDA has recognized EDC as an important enabling technology, and the agency is strengthening requirements for its use.
With the advent of technology and the ability to reach consumers across country boundaries, cultural-value based strategy is more important than ever.
Most drug manufacturers are looking for a combination of specialized expertise, integrated project management combined, cost-effective services from CDMOs.
The Nice Insight’s 2015 Pharmaceutical and Biotechnology Outsourcing survey report comprises 240+ questions and includes responses from 2,303 participants.
Cost-cutting, downsizing, thinning pipelines and a lack of blockbusters are leading drug manufacturers to increase their reliance on CDMOs.
As pharmaceutical companies face increasing cost pressures, they are turning to outsourcing partners with expertise.
An Increasing number of innovative small and emerging pharma firms are developing new drug candidates with orphan or breakthrough therapy status.
A 2013 survey of 800 American adults showed that nearly two-thirds of those who take prescription medications do not take their medication properly.
Parenteral drug delivery accounting for 30 percent of market share, is the 2nd largest segment of the pharmaceutical market following solid oral dose delivery.
Faced with stagnating growth in the developed market, pharma companies have increasingly turned to emerging markets for new growth and profit opportunities.
.svg)
